Bangalore, Karnataka -- (SBWIRE) -- 01/25/2017 -- The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.

Report forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro

Other prominent vendors
- Acacia Pharma
- Aphios
- Baxter Healthcare
- Dr. Reddy's Laboratories
- Eisai
- Especificos Stendhal
- F. Hoffmann-La Roche
- Kyowa Hakko Kirin
- Lee's Pharmaceutical Holdings
- Midatech Pharma
- Mundipharma
- Mylan
- Ono Pharmaceutical
- OPKO Health
- Orchid Chemicals & Pharmaceuticals
- Otsuka Pharmaceutical
- Purdue Pharma
- Sandoz (a subsidiary of Novartis)
- SciClone Pharmaceuticals
- Shin Nippon Biomedical Laboratories
- Solasia Pharma K.K.
- Specialised Therapeutics
- Sun Pharma
- Taiho Pharmaceutical
- Teva Pharmaceuticals

Market driver
- Growing preference of chemotherapy drugs in developing countries
- For a full, detailed list, view our report

Market challenge
- Growing popularity of alternate therapies for the treatment of cancer in developed countries
- For a full, detailed list, view our report

Market trend
- Increasing inorganic growth strategies likely to fuel the market growth
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 77 pages "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Disease overview, Pipeline analysis, Market landscape, Market segmentation by therapy, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-chemotherapy-induced-nausea-and-vomiting-drugs-market-2017-2021

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.